喹诺酮类药物治疗社区获得性肺炎疗效观察与安全性评价

Efficacy and safety of carbostyril in patients with community-acquired pneumonia

目的探讨3种喹诺酮类药物治疗社区获得性肺炎的疗效和安全性,为临床治疗性用药提供科学依据。方法采用随机、开放对照的研究方法,选取120例社区获得性肺炎患者,随机分为莫西沙星组、左氧氟沙星组和环丙沙星组3组,每组各40例,治疗7d后比较3组临床与细菌学疗效和安全性。结果莫西沙星组总有效率为93%,细菌清除率为88.9%,不良反应的发生率为7.5%;左氧氟沙星总有效率为88%,细菌清除率为76.5%,不良反应的发生率为73.3%;环丙沙星总有效率为88%,细菌清除率为73.3%,不良反应的发生率为7.5%。3组总有效率和不良反应发生率比较差异无统计学意义,细菌清除率莫西沙星组要高于左氧氟沙星组和环丙沙星组,差异有统计学意义(P<0.05)。结论经验性莫西沙星、左氧氟沙星与环丙沙星治疗社区获得性肺炎的总的临床疗效和安全性基本一致,但莫西沙星具有更强的细菌清除率。

Objective To investigate the efficacy and safety of carbostyril moxifloxacin hydrochloride （Avelox）,Levofloxacin （Cravit） and Ciprofloxacin（Ciprobay） in patients with community-acquired pneumonia （CAP） and to provide the diagnosis reference.Methods One hundred twenty patients with CAP were randomly divided into three groups：Moxifloxacin group,Levofloxacin group and Ciprofloxacing group in an open clinical study.Clinical and bacteriological efficacy and safety were evaluated after 7 days of treatment.Results The total effective rate in Moxifloxacin,Levofloxacin and Ciprofloxacin treatment group was 93%,88% and 88%,respectively.The bacterial eradication rate in Moxifloxacin,Levofloxacin and Ciprofloxacin treatment group was 88.9%,76.5% and 73.3%,respectively.The adverse drug reaction rate was 7.5%,10% and 7.5%,respectively.There was no significantly difference in the effective rate and adverse drug reaction rate in the three groups（P0.05）.Bacterial eradication rate of Moxifloxacin treatment group was better than Levofloxacin and Ciprofloxacin.Conclusion Moxifloxacin had a better bacterial eradication rate than Levofloxacin and Ciprofloxacin in the treatment of community acquired pneumonia.